Gentuity

Executive Summary

Gentuity is a privately held medical device company based in Memphis, Tennessee, focused on developing innovative micro-imaging catheters for the ophthalmology market. Its lead product, the Vis-Rx Micro-Imaging Catheter, features an ultra-small crossing profile (less than half the size of conventional intravascular imaging catheters), enabling imaging of vessels as small as 1.3 mm and up to 6.0 mm without pre-dilation. This design reduces procedural time and minimizes risk of lesion disruption. Founded in 2014, the company has not disclosed total funding or valuation. Gentuity addresses a clear unmet need in treating small, complex coronary or peripheral lesions, offering a differentiated technology in the competitive intravascular imaging space. While limited public information exists on commercial traction or clinical data, the product's technical advantages and potential for improved patient outcomes position it for adoption among interventional cardiologists and ophthalmologists. Near-term progress likely depends on regulatory clearances, clinical evidence generation, and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Expanded Indications65% success
• Q2 2027First-in-Human or Clinical Study Results50% success
• Q3 2026Strategic Partnership or Distribution Agreement40% success